Stockreport

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]

Elicio Therapeutics, Inc.  (ELTX) 
PDF ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR Annual Meeting [Read more]